KS18, a Mcl-1 inhibitor, improves the effectiveness of bortezomib and overcomes resistance in refractory multiple myeloma by triggering intrinsic apoptosis

Despite a record number of clinical studies investigating various anti-myeloma treatments, the 5-year survival rate for multiple myeloma (MM) patients in the US is only 55%, and almost all patients relapse. Poor patient outcomes demonstrate that myeloma cells are “born to survive” which means they c...

Full description

Bibliographic Details

Published in:	Frontiers in Pharmacology
Main Authors:	Omar S. Al-Odat, Weam Othman Elbezanti, Krishne Gowda, Sandeep K. Srivastava, Shantu G. Amin, Subash C. Jonnalagadda, Tulin Budak-Alpdogan, Manoj K. Pandey
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-10-01
Subjects:	multiple myeloma (MM) Bcl-2 Mcl-1 bortezomib venetoclax refractory
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1436786/full